Peptides vs HGH. They're not the same thing.

Quick comparison at a glance

The short version — here is how GH Secretagogue Peptides and Human Growth Hormone (HGH / Somatropin) stack up on the questions most patients ask before picking one.

GH Secretagogue Peptides

• Drug class: Small synthetic peptides that stimulate pituitary GH release
• Brand names: Sermorelin, CJC-1295, Ipamorelin (compounded)
• Mechanism: Bind receptors on the pituitary (GHRH receptor for GHRH analogs like sermorelin and CJC-1295; GHSR/ghrelin receptor for Ipamorelin) to stimulate release of the body's own growth hormone in natural pulses. The feedback loop stays intact.
• Dosing: Subcutaneous injection, typically daily or several times per week, depending on the specific peptide and protocol.
• Half-life: Varies by peptide — minutes for sermorelin, hours to days for CJC-1295 analogs, hours for Ipamorelin.
• FDA indication: Sermorelin was historically FDA-approved as a diagnostic and therapeutic agent for pediatric GH deficiency but is no longer commercially available. CJC-1295 and Ipamorelin are not FDA-approved for any indication.
• FDA status: Available through licensed compounding pharmacies under valid prescriptions. Not FDA-approved as finished drug products.
• Manufacturer: Licensed compounding pharmacies.
• Common side effects: Injection site reactions, flushing, headache. Milder profile than exogenous HGH because GH release is pulsatile and subject to feedback suppression.
• Typical price range: Compounded GH secretagogue programs typically run $200-$450/month depending on the peptide, dose, and pharmacy.

Human Growth Hormone (HGH / Somatropin)

• Drug class: Recombinant human growth hormone (biologic)
• Brand names: Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Zomacton
• Mechanism: Full 191-amino-acid growth hormone molecule, manufactured through recombinant DNA technology, administered as a subcutaneous injection that directly raises circulating GH.
• Dosing: Subcutaneous injection, daily or several times per week, at doses specific to the FDA-approved indication and patient weight.
• Half-life: Approximately 2-4 hours, but biological effects persist longer through downstream IGF-1 and other signaling.
• FDA indication: Pediatric growth hormone deficiency, adult growth hormone deficiency (with documented pituitary failure), Turner syndrome, Prader-Willi syndrome, HIV-associated wasting, short bowel syndrome, and a handful of other rare conditions.
• FDA status: FDA-approved as multiple brand products for specific indications. Distribution or use for any non-approved purpose (anti-aging, athletic performance, bodybuilding) is illegal under 21 U.S.C. § 333(e).
• Manufacturer: Pfizer (Genotropin), Eli Lilly (Humatrope), Novo Nordisk (Norditropin), and others.
• Common side effects: Joint and muscle pain, fluid retention (edema), carpal tunnel syndrome, insulin resistance, glucose intolerance, and in rare cases, benign intracranial hypertension. Long-term safety concerns include theoretical cancer risks that have been debated for decades.
• Typical price range: Cost varies by product and indication; retail pricing ranges from $1,000 to $3,000+/month without insurance. Insurance coverage is possible only for documented FDA-approved indications, typically with specialist endocrinology oversight.

The legal reality: 21 U.S.C. § 333(e)

Under 21 U.S.C. § 333(e), it is a federal crime to knowingly distribute, or possess with intent to distribute, human growth hormone for any use other than one FDA-approved for the treatment of a disease or other recognized medical condition. This is not a gray area.

The statute was enacted in 1988 specifically to address the non-medical use of HGH for performance enhancement and anti-aging. It carries penalties of up to 5 years imprisonment for simple distribution, and longer sentences for distribution to minors or distribution that results in harm. The DEA and FDA have prosecuted physicians, pharmacies, and distributors for violating this statute.

This means a legitimate HGH prescription in the US requires documented clinical diagnosis of growth hormone deficiency (or another FDA-approved indication), appropriate testing (stimulation testing, IGF-1, pituitary imaging), and ongoing specialist oversight. It is not something a physician can "just prescribe" for anti-aging purposes — doing so would be illegal.

The clinical reality: what each actually does

Beyond the legal distinction, there is a clinical distinction worth understanding:

HGH produces continuous, non-pulsatile GH elevation

When you inject HGH, growth hormone levels rise and stay elevated for several hours at once, overriding your body's natural pulsatile release pattern and suppressing your pituitary. This is appropriate for patients with severe growth hormone deficiency who need replacement therapy. It is not physiologic for healthy adults.

Peptides preserve natural pulsatility

GH secretagogue peptides signal your pituitary to release more of its own growth hormone in natural pulses, while keeping the feedback loops intact. If somatostatin is suppressing the pituitary because IGF-1 is already adequate, sermorelin won't override that — the release is dampened. This is theoretically a gentler approach, but it also means the magnitude of effect is generally smaller.

Neither approach is "better" in the abstract. HGH is appropriate for specific medical indications. Peptides are a different tool with a different risk-benefit profile and a different legal status. Choosing between them is not a matter of preference — it is a matter of clinical indication.

Safety profiles: what's actually known

HGH has decades of clinical data in specific patient populations. Known side effects include joint and muscle pain, fluid retention, carpal tunnel syndrome, and insulin resistance. Long-term cancer risk has been debated for years, with epidemiological studies producing mixed results, and the data specifically on HGH use in healthy adults for anti-aging purposes is essentially nonexistent because such use is illegal.

Compounded GH secretagogue peptides have much less long-term human safety data. The mechanistic argument is that preserving natural feedback makes them safer than exogenous HGH, and short-term side effects reported are generally milder. But "short-term side effects are milder" and "definitely safe for long-term use" are not the same statement. A responsible physician acknowledges this.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

GH Secretagogue Peptides

Peptides tend to fit patients who want a physiological approach to GH optimization — preserving natural pulsatility and feedback regulation. They are prescribed off-label by physicians focused on age-related GH decline in appropriate candidates, and are NOT a legal substitute for HGH in patients with clinically documented growth hormone deficiency.

Human Growth Hormone (HGH / Somatropin)

HGH is appropriate only for patients with documented growth hormone deficiency or one of the other FDA-approved indications. It is prescribed by endocrinologists after clinical testing (typically including GH stimulation tests, IGF-1 labs, and MRI imaging to rule out pituitary pathology). Puri does not prescribe HGH.